Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 3, 2010, Pages 696-702

  Herchenhorn, Daniel ^a   Dias, Fernando L ^a   Viegas, Célia M P ^a   Federico, Miriam H ^b   Araújo, Carlos Manoel M ^a   Small, Isabelle ^a   Bezerra, Marcos ^a   Fontão, Karina ^c   Knust, Renata E ^a   Ferreira, Carlos G ^a   Martins, Renato G ^d  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Roger Abdelmassih Human Reproduction Clinic   (Brazil)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Erlotinib; Radiotherapy; Squamous cell carcinoma

Indexed keywords

CIS-PLATIN; COMPLETE RESPONSE; CONFIDENCE INTERVAL; DOSE LIMITING TOXICITY; DURING PHASE; EPIDERMAL GROWTH FACTOR RECEPTORS; ERLOTINIB; HEAD-AND-NECK SQUAMOUS CELL CARCINOMA; IN-FIELD; IN-PHASE; NONHEMATOLOGIC TOXICITY; OVERALL SURVIVAL RATES; PHASE I; PHASE II; RESIDUAL DISEASE; SALVAGE SURGERY; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECKS; SYNERGISTIC INTERACTION; TYROSINE KINASE INHIBITOR; XEROSTOMIA;

AMINO ACIDS; CHEMOTHERAPY; ENZYME INHIBITION; PEPTIDES; PHOSPHATASES; PLATINUM COMPOUNDS; TOXICITY;

RADIOTHERAPY;

CISPLATIN; ERLOTINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CREATININE CLEARANCE; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; INFECTION; KIDNEY FAILURE; MALE; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SEPSIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; XEROSTOMIA; BRAZIL; CARCINOMA, SQUAMOUS CELL; CONFIDENCE INTERVAL; DRUG ADMINISTRATION; DRUG ERUPTIONS; HEAD AND NECK NEOPLASMS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OROPHARYNGEAL NEOPLASMS; PATHOLOGY; PROCEDURES; RADIATION DOSE; SALVAGE THERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAZIL; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; QUINAZOLINES; RADIOTHERAPY DOSAGE; SALVAGE THERAPY; SURVIVAL RATE;

EID: 77957195929     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.08.079     Document Type: Article

References (41)

1. Brazil Ministry of Health, Secretariat for Health Assistance, National Cancer Institute, Prevention and Surveillance Coordination Unit Estimate 2008: Brazilian cancer incidence 2007 NCI Rio de Janeiro
2. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66
3. J.L. Lefebvre Current clinical outcomes demand new treatment options for SCCHN Ann Oncol 16 Suppl. 6 2005 vi7 vi12
4. D.J. Adelstein, Y. Li, and G.L. Adams An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable SCC head and neck cancer J Clin Oncol 21 2003 92 98
5. R.J. Bensadoun, O. Dassonville, and A. Ramaioli Phase III multicenter randomized study of concurrent twice-a-day radiotherapy with and without cisplatin-5FU (BiRCF) in unresectable pharyngeal carcinoma [Abstract] J Clin Oncol 22 Suppl. 2004 5504
6. D.J. Adelstein, P. Lavertu, and J.P. Saxton Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV SCC of the head and neck Cancer 88 2000 876 883
7. A.A. Forastiere, H. Goepfert, and M. Maor Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N Engl J Med 349 2003 2091 2098
8. S. Kalyankrishna, and J.R. Grandis Epidermal growth factor receptor biology in HN cancer J Clin Oncol 24 2006 2666 2672
9. M. Maurizi, G. Scambia, and P. Benedetti Panici EGF receptor expression in primary laryngeal cancer: Correlation with clinico-pathological features and prognostic significance Int J Cancer 52 1992 862 866
10. O. Dassonville, J.L. Formento, and M. Francoual Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer J Clin Oncol 11 1993 1873 1878
11. W.J. Issing, C. Liebich, and T.P. Wustrow Coexpression of epidermal growth factor receptor and TGF-alpha and survival in upper aerodigestive tract cancer Anticancer Res 16 1996 283 288
12. Q.H. Wen, T. Miwa, and T. Yoshizaki Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy Laryngoscope 106 1996 884 888 (Pubitemid 26242129)
13. J. Rubin Grandis, M.F. Melhem, and W.E. Gooding Levels of TGF-alpha and EGFR protein in HN squamous cell carcinoma and patient survival J Natl Cancer Inst 90 1998 824 832
14. G. Almadori, G. Cadoni, and J. Galli Epidermal growth factor receptor expression in primary laryngeal cancer: An independent prognostic factor of neck node relapse Int J Cancer 84 1999 188 191
15. N. Magne, X. Pivot, and R.J. Bensadoun The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy Eur J Cancer 37 2001 2169 2177
16. C.W. Reuter, M.A. Morgan, and A. Eckardt Targeting EGF-receptor- signalling in SCC of the head and neck Br J Cancer 96 2007 408 416
17. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for SCC of the head and neck N Engl J Med 354 2006 567 578
18. K. Liang, K.K. Ang, and L. Milas The epidermal growth factor receptor mediates radioresistance Int J Radiat Oncol Biol Phys 57 2003 246 254
19. D. Soulieres, N.N. Senzer, and E.E. Vokes Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic SCC of the head and neck J Clin Oncol 22 2004 77 85
20. L.L. Siu, D. Soulieres, and E.X. Chen Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic SCC of the head and neck J Clin Oncol 25 2007 2178 2183
21. E.S. Kim, M.S. Kies, and B.S. Glisson Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [Abstract] J Clin Oncol 25 Suppl. 2007 6013
22. American Joint Committee on Cancer AJCC cancer staging manual 6th ed. 2002 Lippincott Williams & Wilkins Philadelphia
23. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
24. C.A. Perez, L.W. Brady, E.C. Halperin, and R.K. Schmidt-Ullrich Principles and practice of radiation oncology 4th ed. 2004 Lippincott Williams & Wilkins Philadelphia p. 918-1178
25. E.A. Eisenhauera, P. Therasseb, and J. Bogaertsc New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
26. W. Budach, T. Hehr, and V. Budach A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced SCC of the head and neck BMC Cancer 6 2006 28
27. J.M. Bachaud, E. Cohen-Jonathan, and C. Alzieu Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced HN carcinoma: Final report of a randomized trial Int J Radiat Oncol Biol Phys 36 1996 999 1004
28. D.J. Adelstein, J.P. Saxton, and P. Lavertu A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV SCC head and neck cancer Head Neck 19 1997 567 575 (Pubitemid 27407310)
29. B. Jeremic, Y. Shibamoto, and B. Milicic Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced SCC of the head and neck: A prospective randomized trial J Clin Oncol 18 2000 1458 1464
30. B. Jeremic, Y. Shibamoto, and B. Stanisavljevic Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable SCC of the head and neck: A prospective randomized trial Radiother Oncol 43 1997 29 37
31. D.G. Pfister, Y.B. Su, and D.H. Kraus Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, SCC head and neck cancer: A pilot phase II study of a new combined-modality paradigm J Clin Oncol 24 2006 1072 1078
32. C.J. Langer, J.W. Lee, and A. Patel Preliminary analysis of ECOG 3303: Concurrent radiation, cisplatin and cetuximab in unresectable locally advanced squamous cell carcinoma of the head and neck [Abstract] J Clin Oncol 26 Suppl. 2008 A6606
33. H.J. Wanebo, M. Ghebremichael, and B. Burtness Phase II evaluation of: Cetuximab combined with induction paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cell carcinoma of the head and neck [Abstract] J Clin Oncol 25 Suppl. 2007 A6015
34. Ang KK. A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (C225) [followed by surgery for selected patients] for stage III and IV head and neck carcinomas. NCI protocols. Available from: URL: http://www.cancer.gov/ search/ViewClinicalTrials.aspx?cdrid=458049&version= HealthProfessional%26protocolsearchid=5996915. Accessed March 30, 2009.
35. A. Nogueira-Rodrigues, C.C. do Carmo, and C. Viegas Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer Clin Cancer Res 14 2008 6324 6329
36. W. Budach, E. Bolke, and B. Homey Severe cutaneous reaction during radiation therapy with concurrent cetuximab N Engl J Med 357 2007 514 515
37. D.M. Brizel, M.E. Albers, and S.R. Fisher Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced HN cancer N Engl J Med 338 1998 1798 1804
38. G. Calais, M. Alfonsi, and E. Bardet Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma J Natl Cancer Inst 91 1999 2081 2086
39. R.A. Velazquez, H.S. McGuff, and D. Sycamore The role of computed tomographic scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy Arch Otolaryngol Head Neck Surg 130 2004 74 77
40. S. Maheswaran, L.V. Sequist, and S. Nagrath Detection of mutations in EGFR in circulating lung-cancer cells N Engl J Med 359 2008 366 377
41. M. Agulnik, G.C. Santos, and D. Hedley Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic SCC of the head and neck treated with erlotinib J Clin Oncol 25 2007 2184 2190